CENTOGENE to Participate in Upcoming Partnering Conferences in October
October 06, 2022 06:00 ET
|
Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the commercial-stage essential biodata life science partner for rare and...
CENTOGENE Reaches 12,500 Patient Milestone in World’s Largest Observational Study on Parkinson’s Disease Genetics
October 03, 2022 08:00 ET
|
Centogene NV
Working together with Denali Therapeutics to accelerate data-driven precision medicine for the PD community Rostock International Parkinson's Disease (ROPAD) Study aims to characterize the genetics...
CENTOGENE to Present at Upcoming Investor & Partnering Conferences in September
September 01, 2022 06:30 ET
|
Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the commercial-stage essential biodata life science partner for rare and...
CENTOGENE Reports First Quarter 2022 Financial Results
July 15, 2022 08:15 ET
|
Centogene NV
On Track for FY 2022 Guidance Q1 2022 revenue rises 3% to €10.3 million Completed phase out of COVID-19 Business segment in Q1 2022Positioning Pharma and Diagnostics for post-COVID recovery and...
CENTOGENE Announces Appointment of Miguel Coego Rios as Chief Financial Officer
June 27, 2022 16:01 ET
|
Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, June 27, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the commercial-stage, essential biodata life science partner for rare and...
CENTOGENE Announces Shareholder Approval of All Resolutions at 2022 Annual General Meeting
June 27, 2022 16:01 ET
|
Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 27, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the commercial-stage, essential biodata life science partner for rare and...
CENTOGENE and Agios Expand Partnership for Clinical Development of PYRUKYND® (mitapivat) to Treat Children With Rare Blood Disease
June 13, 2022 06:30 ET
|
Centogene NV
Expanded collaboration to include Phase 3 ACTIVATE-kids and ACTIVATE-kidsT studies CENTOGENE’s genetic testing and Biodatabank identify causative mutations, including the UGT1A1 and PKLR genes, and...
CENTOGENE’s CentoCloud® Is Now CE-Marked as One of the Only Decentralized SaaS Platforms Compliant With European IVD Regulatory Framework
May 25, 2022 06:30 ET
|
Centogene NV
CentoCloud, CENTOGENE’s cloud-based Software as a Service (SaaS) platform, is CE-marked under the In Vitro Diagnostics Directive (98/79/EC)CE-marking is required for all in vitro diagnostic (IVD)...
CENTOGENE Contributes to Europe-Wide Efforts to Update Guidelines for Whole Genome Sequencing (WGS) in Rare Disease Diagnostics
May 23, 2022 06:30 ET
|
Centogene NV
Newly established WGS recommendations published in the European Journal of Human Genetics Collaborative initiative leverages CENTOGENE’s differentiated diagnostic expertise with testing performed in...
CENTOGENE to Present at the H.C. Wainwright Global Investment Conference
May 19, 2022 06:30 ET
|
Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 19, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the commercial-stage essential biodata life science partner for rare and...